Find A Research Study
Study Title: CombiRx
Category: Neurology
Currently accepting participants?
Yes - please read the description below and contact the study coordinator if you are interested.
Principal Investigator: Mariko Kita
Study Coordinator: Lieslie Stevens
Phone: 206-625-7373 Ext.61386
Email: leslie.stevens@vmmc.org
What is the CombiRx study?
Who can participate?
with Relapsing Remitting Multiple Sclerosis.
What do I have to do as a study participant?
Virginia Mason Medical Center for a variety of
procedures that may include: physical exams,
neurological exams, blood draws, ECGs, MRIs, and
injection training to administer the study
drugs. The study will last 3 years.
Study Summary:
Detailed Study Description:
Study Design: Interventional
Phase of Study: n/a
Study Type: Interventional
Condition or Study Focus: Relapsing Remitting Multiple Sclerosis
Intervention Type: Pillcam
Intervention Name: Interferon Beta-1a and Glatiramer Acetate
Gender: Male and Female
Age group: Interventional
Sponsor: _
Other studies in this category include:
Studies currently accepting study participants:
- CombiRx
- Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis II
- Novartis Fingolimod MS Study
- Relapsing - Remitting MS: A Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of oral BG00012
Studies currently not accepting study participants:
No studies currently listed. Please try another category.